Reneo Pharmaceuticals Inc.

Hepatic Function

Reneo Pharmaceuticals Inc. is focused on clinical research involving impaired hepatic function, with attention to how investigational therapies are handled in people with normal liver function and varying degrees of hepatic impairment.

  • Normal hepatic function
  • Mild hepatic impairment
  • Moderate hepatic impairment
  • Severe hepatic impairment

The sponsor’s research interest centers on pharmacokinetics in liver-compromised populations, supporting evaluation of treatment behavior across clinically relevant levels of liver dysfunction.

Metabolic and Organ-Specific Drug Handling

The clinical program reflects interest in how medicines are processed in the presence of altered hepatic metabolism, with relevance to patients whose organ function may affect exposure and response.

  • Drug disposition
  • Organ impairment assessment
  • Exposure evaluation

This area supports development work aimed at understanding therapeutic use in populations with reduced liver clearance and other impairment-related changes.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Phase 1 Study of REN001 Single‑Dose Pharmacokinetics in Adults with Normal, Mild, Moderate, or Severe Liver Impairment

    Not recruiting

    1 1
    Hungary